Starpharma Holdings Ltd (SPHRY)

Starpharma Holdings Ltd is an Australian biopharmaceutical company whose ordinary shares are represented in the U.S. OTC market through this depositary receipt listing. The company focuses on researching, developing, and commercializing dendrimer-based technology for pharmaceutical, healthcare, life science, and related applications in Australia and abroad. Its portfolio includes VivaGel BV, a non-antibiotic vaginal gel used for bacterial vaginosis and recurrent BV prevention, as well as VIRALEZE, an antiviral nasal spray, and VivaGel condom, an antiviral condom coating. Starpharma is also advancing several dendrimer-enhanced product candidates, including DEP SN38, DEP cabazitaxel, and DEP docetaxel, all in Phase II clinical testing for different cancer indications. Additional programs include DEP HER2 radiodiagnostic, DEP HER2 ADC, and other antibody-drug conjugate development initiatives. Incorporated in 1997 and based in Abbotsford, Australia, the company also has a collaboration with Medicxi to develop petalion therapeutics using its dendrimer technology.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.